Thrombotic Microangiopathy with Renal Injury: An Approach for the General Physician

Abstract

Thrombotic microangiopathy with renal dysfunction is a haematological and renal emergency warranting urgent diagnosis and intervention. As the potential underlying causes may be complex, assessment and management can be challenging for treating clinicians, and a timely and collaborative approach between general physicians, haematologists and nephrologists may be extremely helpful in order to optimise clinical outcomes. This paper will aim to build an understanding of different potential presentations of thrombotic microangiopathies and provide a practical framework for diagnosis and management, using a case-based discussion format, for acute and general physicians. Some aspects of subsequent specialist management are also discussed.

Keywords

haemolytic uraemic syndrome microangiopathic haemolytic anaemia renal injury thrombotic microangiopathy thrombotic thrombocytopenic purpura

Get full access to this article

View all access options for this article.

References

George

, Nester

. Syndromes of thrombotic microangiopathy. N Engl J Med 2014; 371: 654–66.

Moake

. Thrombotic microangiopathies. N Engl J Med 2002; 347: 589–600.

Salvadori

, Bertoni

. Update on hemolytic uremic syndrome: diagnostic and therapeutic recommendations. World J Nephrol 2013; 2: 56–76.

Brocklebank

, Wood

, Kavanagh

. Thrombotic microangiopathy and the kidney. Clin J Am Soc Nephrol 2018; 13: 300–17.

Scully

, Yarranton

, Liesner

. Regional UK TTP registry: correlation with laboratory ADAMTS 13 analysis and clinical features. Br J Haematol 2008; 142: 819–26.

Noris

, Remuzzi

. Hemolytic uremic syndrome. J Am Soc Nephrol 2005; 16: 1035–50.

Tsai

. Current concepts in thrombotic thrombocytopenic purpura. Annu Rev Med 2006; 57: 419–36.

Kremer Hovinga

, Coppo

, Lammle

. Thrombotic thrombocytopenic purpura. Nat Rev Dis Primers 2017; 3:17020.

Loirat

, Fremeaux-Bacchi

. Atypical hemolytic uremic syndrome. Orphanet J Rare Dis 2011; 6:60.

10.

Page

, Kremer Hovinga

, Terrell

. Thrombotic thrombocytopenic purpura: diagnostic criteria, clinical features, and long-term outcomes from 1995 through 2015. Blood Adv 2017; 1: 590–600.

11.

George

. How I treat patients with thrombotic thrombocytopenic purpura: 2010. Blood 2010; 116: 4060–9.

12.

Mannucci

, Peyvandi

. TTP and ADAMTS13: when is testing appropriate? Hematol Am Soc Hematol Educ Program 2007:121–6.

13.

Fontana

, Kremer Hovinga

, Lammle

. Treatment of thrombotic thrombocytopenic purpura. Vox Sang 2006; 90: 245–54.

14.

Chen

, Fu

, Wang

. Rituximab as first-line treatment for acquired thrombotic thrombocytopenic purpura. J Int Med Res 2017; 45: 1253–60.

15.

Scully

, Cataland

, Peyvandi

. Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura. N Engl J Med 2019; 380: 335–46.

16.

Polito

, Kirsztajn

. Thrombotic microangiopathies: thrombotic thrombocytopenic purpura / hemolytic uremic syndrome. J Bras Nefrol 2010; 32: 303–15.

17.

Petruzziello-Pellegrini

, Marsden

. Shiga toxin-associated hemolytic uremic syndrome: advances in pathogenesis and therapeutics. Curr Opin Nephrol Hypertens 2012; 21: 433–40.

18.

Tarr

, Gordon

, Chandler

Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome. Lancet 2005; 365: 1073–86.

19.

Brandt

, Fouser

, Watkins

. Escherichia coli O 157: H7-associated hemolytic-uremic syndrome after ingestion of contaminated hamburgers. J Pediatr 1994; 125: 519–26.

20.

Loos

, Aulbert

, Hoppe

. intermediate follow-up of pediatric patients with hemolytic uremic syndrome during the 2011 outbreak caused by E. coli O104: H4. Clin Infect Dis 2017; 64: 1637–43.

21.

Spinale

, Ruebner

, Copelovitch

. Long-term outcomes of Shiga toxin hemolytic uremic syndrome. Pediatr Nephrol 2013; 28: 2097–105.

22.

Iijima

, Kamioka

, Nozu

. Management of diarrhea-associated hemolytic uremic syndrome in children. Clin Exp Nephrol 2008; 12: 16–9.

23.

Noris

, Remuzzi

. Atypical hemolytic-uremic syndrome. N Engl J Med 2009; 361: 1676–87.

24.

Sellier-Leclerc

, Fremeaux-Bacchi

, Dragon-Durey

. Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome. J Am Soc Nephrol 2007; 18: 2392–400.

25.

Noris

, Ruggenenti

. Kidney transplantation in patients with atypical hemolytic uremic syndrome: a therapeutic dilemma (or not)? Am J Kidney Dis 2017; 70: 754–7.

26.

Legendre

, Licht

, Muus

. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med 2013; 368: 2169–81.

27.

Page

, Little

, Vesely

. Quinine-Induced thrombotic microangiopathy: a report of 19 patients. Am J Kidney Dis 2017; 70: 686–95.

28.

Zakarija

, Bennett

. Drug-induced thrombotic microangiopathy. Semin Thromb Hemost 2005; 31: 681–90.

29.

Medina

, Sipols

, George

. Drug-associated thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Curr Opin Hematol 2001; 8: 286–93.

30.

George

, Nester

, McIntosh

. Syndromes of thrombotic microangiopathy associated with pregnancy. Hematol Am Soc Hematol Educ Program 2015; 2015: 644–8.

31.

Fakhouri

, Vercel

, Fremeaux-Bacchi

. Obstetric nephrology: AKI and thrombotic microangiopathies in pregnancy. Clin J Am Soc Nephrol 2012; 7: 2100–6.

32.

Chen

M-H

, Chen

M-H

, Chen

W-S

. Thrombotic microangiopathy in systemic lupus erythematosus: a cohort study in North Taiwan. Rheumatology 2010; 50: 768–75.

33.

Brocklebank

, Kavanagh

. Complement C5-inhibiting therapy for the thrombotic microangiopathies: accumulating evidence, but not a panacea. Clin Kidney J 2017; 10: 600–24.

34.

Woodworth

, Suliman

, Li

. Scleroderma renal crisis and renal involvement in systemic sclerosis. Nat Rev Nephrol 2016; 12: 678–91.

35.

Scully

. Cancer and thrombotic microangiopathy. J Oncol Pract 2016; 12: 531–2.

36.

Izzedine

, Perazella

. Thrombotic microangiopathy, cancer, and cancer drugs. Am J Kidney Dis 2015; 66: 857–68.

37.

Govind Babu

, Bhat

. Cancer-associated thrombotic microangiopathy. Ecancermedicalscience 2016; 10:649.

38.

George

. Systemic malignancies as a cause of unexpected microangiopathic hemolytic anemia and thrombocytopenia. Oncology 2011; 25: 908–14.

39.

Abbas

, El Kossi

, Kim

. Thrombotic microangiopathy after renal transplantation: Current insights in de novo and recurrent disease. World J Transplant 2018; 8: 122–41.

40.

Noris

, Remuzzi

. Thrombotic microangiopathy after kidney transplantation. Am J Transplant 2010; 10: 1517–23.

41.

Garg

, Rennke

, Pavlakis

. De novo thrombotic microangiopathy after kidney transplantation. Transplant Rev 2018; 32: 58–68.

42.

Java

, Edwards

, Rossi

. Cytomegalovirus-induced thrombotic microangiopathy after renal transplant successfully treated with eculizumab: case report and review of the literature. Transpl Int 2015; 28: 1121–5.

43.

Obut

, Kasinath

, Abdi

. Post-bone marrow transplant thrombotic microangiopathy. Bone Marrow Transplant 2016; 51: 891–7.

44.

Khanal

, Dahal

, Upadhyay

. Differentiating malignant hypertension-induced thrombotic microangiopathy from thrombotic thrombocytopenic purpura. Ther Adv Hematol 2015; 6: 97–102.

45.

Shavit

, Reinus

, Slotki

. Severe renal failure and microangiopathic hemolysis induced by malignant hypertension—case series and review of literature. Clin Nephrol 2010; 73: 147–52.